Having trouble accessing articles? Reset your cache.

Gene therapy readout helps Ultragenyx rebound

Orphan disease company Ultragenyx added nearly $600 million in market cap Friday after reporting better-than-expected data for gene therapy DTX301 -- a welcome lift after clinical disappointments had weighed on the stock in 2H19.

After

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE